Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.50 |
| ▸ | PDE4A | P27815 | 9/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7084190 | 1.00 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| SCHEMBL905908 | 1.00 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| SCHEMBL6876369 | 0.85 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| SCHEMBL5673767 | 0.85 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| SCHEMBL31190158 | 0.84 | PDE4A (0.48) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| SCHEMBL28048197 | 0.84 | PDE4A (0.48) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| SCHEMBL5551736 | 0.83 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL9938956 | 0.83 | SMPD1 (0.47) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| SCHEMBL6876864 | 0.82 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL18920443 | 0.81 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019073431-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST AND ITS INTERMEDIATE | Piramal Enterprises Limited (IN) | 2019-04-18 | — | — | WO | claimed |
| WO-2017179065-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | DAVULURI RAMAMOHAN RAO (IN) | 2017-10-19 | — | — | WO | claimed |
| WO-2016174685-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | MYLAN LABORATORIES LIMITED (IN) | 2016-11-03 | — | — | WO | claimed |
| EP-3619195-A1 | NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE | Unichem Laboratories Ltd (IN) | 2020-03-11 | — | — | EP | disclosed |
| WO-2019073431-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST AND ITS INTERMEDIATE | Piramal Enterprises Limited (IN) | 2019-04-18 | — | — | WO | disclosed |
| WO-2018203192-A1 | NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE | UNICHEM LABORATORIES LTD (IN) | 2018-11-08 | — | — | WO | disclosed |
| WO-2017179065-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | DAVULURI RAMAMOHAN RAO (IN) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-3142663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-3142748-A1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2016174685-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | MYLAN LABORATORIES LIMITED (IN) | 2016-11-03 | — | — | WO | disclosed |
| WO-2013126360-A2 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | CELGENE CORPORATION (US) | 2013-08-29 | — | — | WO | disclosed |
| WO-2012149251-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | CELGENE CORPORATION (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012121988-A2 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012096884-A1 | PHENETHYLSULFONE ISOINDOLINE DERIVATIVES AS INHIBITORS OF PDE 4 AND/OR CYTOKINES | CELGENE CORPORATION (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-2223687-A1 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof | CELGENE CORPORATION (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1965793-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079182-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |